Utah Retirement Systems held its position in shares of Illumina Inc. (NASDAQ:ILMN) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,790 shares of the life sciences company’s stock at the end of the third quarter. Utah Retirement Systems’ holdings in Illumina were worth $4,867,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Clear Harbor Asset Management LLC raised its position in shares of Illumina by 38.5% in the third quarter. Clear Harbor Asset Management LLC now owns 3,599 shares of the life sciences company’s stock valued at $654,000 after buying an additional 1,000 shares in the last quarter. ProVise Management Group LLC raised its position in shares of Illumina by 4.8% in the third quarter. ProVise Management Group LLC now owns 2,402 shares of the life sciences company’s stock valued at $436,000 after buying an additional 110 shares in the last quarter. Pictet & Cie Europe SA bought a new position in shares of Illumina during the third quarter valued at $2,963,000. Robeco Institutional Asset Management B.V. raised its position in shares of Illumina by 1.3% in the third quarter. Robeco Institutional Asset Management B.V. now owns 58,341 shares of the life sciences company’s stock valued at $10,598,000 after buying an additional 736 shares in the last quarter. Finally, Prudential Financial Inc. raised its position in shares of Illumina by 0.3% in the third quarter. Prudential Financial Inc. now owns 202,670 shares of the life sciences company’s stock valued at $36,817,000 after buying an additional 655 shares in the last quarter. 92.98% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Illumina Inc. (NASDAQ:ILMN) traded down 2.48% on Wednesday, hitting $133.14. 2,399,134 shares of the stock traded hands. Illumina Inc. has a 12-month low of $127.10 and a 12-month high of $196.47. The stock has a market capitalization of $19.56 billion, a P/E ratio of 44.68 and a beta of 1.24. The company’s 50 day moving average price is $139.08 and its 200-day moving average price is $152.96.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, November 1st. The life sciences company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $0.10. Illumina had a net margin of 18.72% and a return on equity of 23.76%. The firm had revenue of $607 million for the quarter, compared to analyst estimates of $628.06 million. During the same quarter in the prior year, the firm earned $0.80 EPS. The company’s revenue was up 10.4% on a year-over-year basis. Analysts predict that Illumina Inc. will post $3.32 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Utah Retirement Systems Has $4,867,000 Stake in Illumina Inc. (ILMN)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/30/utah-retirement-systems-has-4867000-stake-in-illumina-inc-ilmn.html.

Several brokerages have weighed in on ILMN. Leerink Swann began coverage on shares of Illumina in a report on Thursday, November 10th. They set a “market perform” rating and a $145.00 price objective for the company. Vetr lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $133.50 price target for the company. in a report on Wednesday, November 9th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $155.00 price target on shares of Illumina in a report on Thursday, November 3rd. BTIG Research reaffirmed a “hold” rating on shares of Illumina in a report on Thursday, November 3rd. Finally, Canaccord Genuity set a $135.00 price target on shares of Illumina and gave the company a “hold” rating in a report on Wednesday, November 2nd. Four research analysts have rated the stock with a sell rating, fifteen have given a hold rating and seven have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $152.88.

In other Illumina news, Director Daniel Bradbury sold 600 shares of the stock in a transaction dated Friday, October 7th. The shares were sold at an average price of $184.36, for a total transaction of $110,616.00. Following the sale, the director now owns 17,065 shares of the company’s stock, valued at approximately $3,146,103.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Robert S. Epstein sold 300 shares of the stock in a transaction dated Tuesday, September 20th. The stock was sold at an average price of $174.29, for a total transaction of $52,287.00. Following the sale, the director now directly owns 6,924 shares in the company, valued at approximately $1,206,783.96. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

5 Day Chart for NASDAQ:ILMN

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.